Aquestive Therapeutics, Inc.

NasdaqGM:AQST Stock Report

Market Cap: US$332.8m

Aquestive Therapeutics Past Earnings Performance

Past criteria checks 0/6

Aquestive Therapeutics has been growing earnings at an average annual rate of 18.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 0.5% per year.

Key information

18.6%

Earnings growth rate

34.8%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate0.5%
Return on equityn/a
Net Margin-59.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Dec 19
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%

Aquestive: Rare Opportunity With Dual Platform Strategy

Nov 05

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Revenue & Expenses Breakdown

How Aquestive Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:AQST Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2459-354418
30 Jun 2458-263916
31 Mar 2452-293515
31 Dec 2351-83213
30 Sep 2348-123414
30 Jun 2347-233915
31 Mar 2347-334716
31 Dec 2248-545317
30 Sep 2248-715618
30 Jun 2250-735619
31 Mar 2252-695318
31 Dec 2151-715317
30 Sep 2147-625417
30 Jun 2142-645420
31 Mar 2148-545519
31 Dec 2046-565620
30 Sep 2055-485719
30 Jun 2059-505916
31 Mar 2049-686121
31 Dec 1953-666421
30 Sep 1953-686723
30 Jun 1954-646523
31 Mar 1957-808323
31 Dec 1867-617223
30 Sep 1863-616124
30 Jun 1877-385525
31 Mar 1874-82722
31 Dec 1767-142522
31 Dec 1652-122115

Quality Earnings: AQST is currently unprofitable.

Growing Profit Margin: AQST is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AQST is unprofitable, but has reduced losses over the past 5 years at a rate of 18.6% per year.

Accelerating Growth: Unable to compare AQST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AQST is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).


Return on Equity

High ROE: AQST's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aquestive Therapeutics, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Gary NachmanBMO Capital Markets Equity Research
Kristen KluskaCantor Fitzgerald & Co.